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Abstract: Magnetic nanoparticle (MNP)-mediated hyperthermia (MH) coupled with radiation
therapy (RT) is a novel approach that has the potential to overcome various practical difficulties
encountered in cancer treatment. In this work, we present recommendations for the in vitro
and in vivo testing and application of the two treatment techniques. These recommendations
were developed by the members of Working Group 3 of COST Action TD 1402: Multifunctional
Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy (“Radiomag”).
The purpose of the recommendations is not to provide definitive answers and directions but, rather,
to outline those tests and considerations that a researcher must address in order to perform in vitro
and in vivo studies. The recommendations are divided into 5 parts: (a) in vitro evaluation of MNPs;
(b) in vitro evaluation of MNP-cell interactions; (c) in vivo evaluation of the MNPs; (d) MH combined
with RT; and (e) pharmacokinetic studies of MNPs. Synthesis and characterization of the MNPs, as
well as RT protocols, are beyond the scope of this work.
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1. Introduction
Radiation therapy (RT) is one of the main treatment approaches for cancer. It is estimated that
50–60% of all cancer patients will receive RT as part of their treatment, either alone as monotherapy
or as part of a combination treatment [1,2]. Over the past 30 years, RT has undergone tremendous
improvement with the introduction of imaging techniques, such as computed tomography (CT),
magnetic resonance imaging (MRI), positron emission tomography (PET), the development of advanced
treatment techniques, such as 3D Conformal RT, Intensity-Modulated RT [3–5], Image-Guided RT [6–8],
Volumetric Modulated Arc Technique [9,10], Stereotactic Body RT [11–13], new modalities, such as
proton therapy [14–16], as well as great strides in understanding tumor biology and its interaction with
radiation [2,17].
Alongside these developments, the efficacy of RT can be increased by combining it with other
forms of treatment, such as Hyperthermia (HT). Beginning in the 1960s, a series of in vitro experiments
demonstrated that although HT by itself cannot provide curative treatment for cancer, it exhibits
high synergy with RT and can significantly improve its potency [18–21]. Specifically, (a) hypoxic cells
that are radio-resistant are heat-sensitive [22–26]; (b) cells in the S-phase that are radio-resistant are
heat-sensitive [27–29]; (c) the low extracellular pH in tumor microenvironment reduces the efficacy
of RT but increases that of HT [30–34]; (d) the abnormal vasculature of the tumor prevents heat
from being carried away, in contrast to normal tissue, thus resulting in selective heating of the
tumor [33,35–38]; and (e) within the tumor, the low blood flow in hypoxic regions results in heat being
trapped [33,35,37,38].
Clinical trials, however, failed to deliver the expected results, primarily due to difficulties in
adequately heating the tumor. This was especially true for deep-seated tumors. For example, a 1996
Phase III study comparing interstitial RT with and without HT for various tumor types, showed that
the addition of HT did not improve treatment results. However, subsequent analysis showed that only
one patient out of 86 in the combined treatment arm of the study had been adequately heated [39].
Nowadays, nanomedicine has been used to develop new ways to induce hyperthermia. For example
gold nanospheres are used in photothermal therapy [40] while some iron oxide nanoparticles have
been specifically designed for magnetic hyperthermia [41].
Magnetic Hyperthermia (MH) is a cutting edge technology, still in its infancy, that is based on the
principle of embedding a heating source, namely magnetic nanoparticles (MNPs), into the targeted
tissue/tumor and heating it by using an external alternating magnetic field [41]. Its attractiveness lies
in the fact that: (a) the MNPs can, in principle, reach deep-seated tumors via the bloodstream [42,43];
(b) the location of the MNPs can be determined using various imaging techniques [44–46]; (c) the
MNPs can also act as temperature probes, providing detailed 3D information about the temperature
distribution in the tumor [47,48]; (d) the MNPs can be functionalized with specific ligands in order to
improve targeting [45,49,50]; (e) the MNPs can be conjugated with chemotherapeutic drugs to increase
the efficacy of magnetic hyperthermia [51]; (f) the technique is minimally invasive, requiring only a
simple injection; and (g) the procedure is rather comfortable since the patient is not required to wear
special suits or be immersed in a thermal bath [52].
To date, MNP-mediated MH combined with RT has only been used to treat recurrent glioblastoma
multiforme, a very aggressive type of brain tumor [53]. With the proviso that this was a
non-randomized, single-arm study, and therefore the results cannot be considered to be definitive,
patient survival increased by several months compared with traditional patterns.
The purpose of this review is not to describe MNPs, their properties, characteristics and potential
uses for MH but, rather, to outline the steps that one needs to take in order to apply the MNPs
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in a pre-clinical setting. These steps include in vitro evaluation of the MNPs themselves and of
MNP-cell interactions, in vivo evaluation, considerations for the combination of MH and RT, and
pharmacokinetic and biodistribution studies. For this reason, we have chosen to format the paper as a
step-by-step, how-to guide.
2. Sample Preparation for In Vitro Evaluation
In vitro evaluation is of paramount importance for further in vivo investigation of MNPs. Samples
revealing marginal or no toxicity via in vitro tests can then move on to in vivo studies. Nevertheless, it
is not unlikely that in vitro and in vivo results are contradictory. This may be attributed to in vivo body
functions and processes. The following recommendations are suggested to make a safe environment
for people starting to work in this new field and to facilitate pre-clinical work using HT in combination
with RT for the treatment of cancer.
Basic requirements for biological in vitro assessment include:
2.1. Colloidal Stability
One of the most used analytical techniques to evaluate the size of nanoparticles is Dynamic Light
Scattering (DLS), and it has been extensively used since it is not time consuming, it is non-invasive
and very sensitive to the presence of small aggregates. This feature can be very helpful when testing
colloidal stability of MNPs [54]. In order to enhance colloidal stability, MNPs are usually functionalized
with various biocompatible compounds (e.g., citrate, phosphate, chitosan, polyethylene glycol,
albumin), since uncoated MNPs tend to flocculate after their introduction to physiologically relevant
fluids. To achieve a better understanding of their behavior when in contact with biorelevant media,
the determination of size and zeta potential as a function of time in different media (culture media,
phosphate buffer, in the absence or presence of Fetal Bovine Serum (FBS)) should be assessed [55].
Indeed, studying interactions between MNPs and plasma and blood platelets for example, can be highly
relevant when looking at their potential clinical application. It has previously been demonstrated
that some types of NPs may lead to platelet aggregation and therefore to thrombus formation [56].
However, it is important to highlight that this detrimental effect can be also reverted, for example, by
introducing PEGylation for improving their compatibility [57]. Another issue to take into account is
the influence of MNP concentration on the size and zeta potential, which should have a negative value
to avoid cytotoxicity. An approximate value of −30 mV should be taken as the reference to assure
colloidal stability. Also, correct DLS measurement relies on the concentration of the sample which, in
turn, is based on the type of the materials and their size. For a correct characterization, an optimal
concentration should be correctly determined.
2.2. Sterilization of the Aqueous MNP Solution
There are several sterilization methods that can be applied to nanomaterials, such as filtration [58,59],
autoclaving [60], irradiation [61], the gas plasma method [62], and others [62]. Endotoxin contamination
is a general problem in clinical use, not specific to nanomaterials. The methods described in
this paragraph are used in general for the removal or destruction of microbial contamination.
In addition, in the case of nanomaterials, it is crucial to investigate how these techniques may affect
the physico-chemical and biological properties of the nanomaterials, such as stability and toxicity [63]
by re-characterization and evaluation.
Sterilization of the Aqueous MNP Solution Using Filtration
Once in aqueous solution, MNPs tend to be prone to contamination. The process of sterilization
by filtration is a commonly used technique to exclude bacteria, mold and yeast. Filtration using a filter
or membrane with a pore size of 0.22 µm or smaller is adequate to remove contaminants of biological
origin. This process does not affect the characteristics of the MNPs, since their size is smaller than that
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of the pore used. Azide is a very toxic substance used to prevent contamination. It is added to the
incubator water at a very low concentration, which does not affect the MNPs.
2.3. MNP Samples Should Be Tested for Endotoxin and Used When Endotoxin-Free
Endotoxins are membrane constituents in most Gram-negative bacteria that can be identified
by immune cells as pathogen-associated molecules. If these compounds are found in nanoparticles
suspension, in vitro results might represent the effect of the contamination and hamper the analysis of
toxicological and inflammatory outcomes associated to MNPs. The FDA recommends validating the
alternative methods for each product to detect endotoxin. This problem is very common in studies
of nanomaterials and it is not easy to eradicate. A common method for endotoxin detection is the
Limulus amoebocyte lysate (LAL) assay, but this type of bioassay is not adequate for all types of MNPs.
Because of the difficulties associated with endotoxin removal, preventing contamination during MNP
synthesis would be the best way for obtaining endotoxin-free particles. This can be achieved by using
only endotoxin-free reagents including water and buffers, instruments and glassware during the
synthesis process [64]. Of particular importance is the reaction solvent. In the case of water, the pH
(extremely acidic or basic) and temperature (high or low) are crucial parameters that must be taken
into consideration. Organic solvents reduce the probability of contamination due to their toxicity.
To store the MNPs for later use, it is better to keep them in the solid phase and apply one of
the techniques suggested shortly before preparing the suspension. MNPs in the solid phase can be
sterilized by exposing them to ultraviolet radiation (UV).
2.4. A High Working Concentration of MNPs Is Recommended
The importance of a high working concentration (>10 mg mL−1) is suggested to widen the tested
conditions. Higher concentrations of MNPs broaden the application of different electric and magnetic
fields according to the intended application. To determine the appropriate concentration of MNPs per
cell for HT, the MNPs should be evaluated at different concentrations and under different frequencies
and power of the magnetic field. All these parameters are related to the shape, size and charge of
the MNPs.
2.5. The Formation of Protein Corona in the Presence of Fetal Bovine Serum
When MNPs are in the blood stream, they interact with albumin, creating a layer on their surface
called the protein-corona layer. It is important to know how the MNP size affects colloidal stability and
the internalization into the cells. The protein corona formed can reduce the toxicity of MNPs, however
the mechanisms involved are still under investigation [65]. The behavior of MNPs in the presence of
albumin can be investigated in vitro, using Fetal Bovine Serum.
2.6. Sonication and Vortexing to Assure Homogeneity of the MNPs
Since colloidal stability is a priority parameter in sample preparation, it is also necessary to avoid
all signs of aggregation. A reproducible concentration-effect response can be obtained only with a
homogeneous solution, which in turn is the result of adequate sonication and vortexing of the samples
under investigation.
2.7. Cells Should Be Confluent but Not Overgrown
In order to proceed to quality cell culture assays, it is important to maintain the morphology
of the chosen cell line. Careful observation of the cells under the microscope upon handling allows
the detection of signs of contamination or detachment and differences in their shape and appearance.
To confirm the handling of a healthy cell line, cells should reach confluence, but never exceed that state
for more than 24 h, to avoid deterioration.
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2.8. Properties of the MNPs
The properties of the MNPs should be determined alone, in vitro and in vivo, before and after
application of Alternating Magnetic Field (AMF) as that may affect their structure and composition.
An example of transmission electron microscopy (TEM), fourier transformed-infrared spectroscopy
(FT-IR), X-ray powder diffraction (XRD) and vibrating sample magnetometer (VSM) characterization is
presented in Figure 1. TEM imaging shows that the MNPs have spherical shapes and their size is about
10± 2 nm (Figure 1A). The FT-IR spectrum of the MNPs has a peak at 545 cm−1, which is characteristic
of the Fe-O bond vibration (Figure 1B). X-ray diffraction (XRD) clearly shows the inverse cubic spinel
structure of Fe3O4 (Figure 1C). Positions of the diffraction peaks (220), (311), (400), (422), (511), (440)
and (533) match well enough with standard XRD patterns for bulk magnetite, indicating that the phase
of the nanoparticles is pure magnetite (Fe3O4). The MNPs are well crystallized and their size can be
estimated using Scherer’s equation [66]. This equation uses the reference peak width at angle 2h = 35.7,
where k is the X-ray wavelength (1.5418 Å); b is the width of the XRD peak at half height, with a value
of 0.446 and is calculated by Lorentzian fitting of the most intense peak (311). K is a shape factor, about
0.9 for magnetite. The estimated size of the MNPs is about 8 nm. The magnetization curve of the MNPs
is presented in Figure 1D, where the saturation magnetization (Ms) is 37.05 emu/g. The high Ms, and
the small size indicate that the MNPs may present super-paramagnetic properties. Even though the
saturation magnetization value is lower than that of bulk magnetite (90 emu/g), it is sufficient for
magnetic hyperthermia applications.
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Figure 1. Typical transmission electron microscopy (TEM) (A), fourier transformed-infrared
spectroscopy (FT-IR) (B), X-ray powder diffraction (XRD) (C) and vibrating sample magnetometer
(VSM) (D) characterization of MNPs (maghemite-magnetite mixture). (Unpublished data).
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3. In Vitro Evaluation of MNP-Cell Interactions
The physico-chemical properties of MNPs facilitate cellular interactions that result in their
biological accumulation. Diverse cellular effects have already been described involving decrease
in cell viability, plasmatic membrane disruption, mitochondrial alterations and even cell cycle arrest
upon exposure to MNPs. The nature of the nanoparticle (e.g., core type and coating material), applied
dose, exposure time, and cell and culture conditions are some of the factors that influence the MNP-cell
interaction [67]. Additionally, the choice of assay to evaluate this process may affect the outcome,
resulting in the controversial studies found in the literature. The design and experimental setup of
each assay should be carefully considered [68]. In this section, we discuss the relevant aspects of the
most commonly used assays to evaluate MNP-cell interactions.
3.1. Toxicity
General toxicity tests, aimed mainly at determining the biological activity of NPs, can be carried
out on many cell types (e.g., fibroblasts, HeLa and hepatoma cells), grown either in suspension (HL60,
K562) or in monolayers (MCF-7, U87MG) and cultured in 75-cm2 flasks (see Table 1). A number
of parameters, including vital staining, cytosolic enzyme release, cell growth and cloning efficiency,
are used as end-points to measure toxicity. The most common and simplest methods to investigate
cell viability are colorimetric assays like 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
(MTT), sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic
acid hydrate (XTT) and others [69,70].
In a typical setup for these assays, cells (100 µL, 1 × 105 cells/mL) are seeded in 96-well
flat-bottomed plates, although their concentration may vary depending on the exposure time to
toxicants. The cells are incubated at 37 ◦C with 5% CO2 for 24, 72, 120 and 168 h (for the 120- and
168-h incubations, the medium is replaced at 72 h with fresh medium containing the appropriate
concentrations of MNPs). The cells are washed three times with PBS and replaced with fresh medium
with the colorimetric substances (100 µL). The absorbance is measured, and the viability of the cells
expressed as a function of concentration and exposure time.
A summary of cytotoxicity studies of MNPs is shown in Table 1 [71].
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Table 1. Brief presentation of recent studies concerning cytotoxicity of MNPs, reproduced from Patil et al. [71]. The references in the table are the references in Patil’s
paper, where more information can be found.
Coating Agent Types of IONPs Diameter (nm) Type of Cells Dose IncubationTime Types of Assay Brief Results Ref.
Silica
Bare IONPs 10 ± 3 Human dermal fibroblasts
(HDFs) and human
fibrosarcoma (HT-1080) in
DMEM media
200–1000 µg/mL 24 h CCK-8 and LDH
APTMS-TEOS-Fe3O4 showed more cytotoxicity in terms
of metabolic activity compared to other MNPs in HDFs.
All MNPs induced LDH leakage in HDFs and
HT-1080 cells.
[62]TEOS-IONPs 100–150
APTMS-TEOS-IONPs 100–150
Bare IONPs 10–50
Peripheral blood lymphocytes
in RPMI media 1–100 µg/mL 2 and 24 h
Annexin V-FIT
Capoptosis
detection
No significant difference between treated and untreated
lymphocytes for 2 and 24 h. [104]
VTES-TEOS-IONPs 10–50
APTES/VTES-TEOS-IONPs 10–50
Bare IONPs
150–200 L L929 fibroblasts in
DMEM media
15–1000 mg/L 24–72 h M
MTT
Silica coating reduced cell toxicity. Sulfhydryl
modification improved cell-compatibility and
haemocompatibility.
[105]TEOS-IONPs
DMSA-TEOS-IONPs
TEOS-IONPs 15–20 MCF-7 and HeLa cells inDMEM media 0–200 µg/mL 24 h M MTT
MCF-7 and HeLa cells showed good biocompatibility at
various concentrations. [106]
PEG
PEG-IONPs ~30 Hela cells and C6 cells inDMEM media 0.01–1 mg/mL 12 h MTT
Cell viability was not affected at the concentration of 1
mg/mL. [107]
PEG-IONPs 10–15 NIH/3T3 in DMEM 1.5 to 192 µM 24 and 48 h MTT PEG-IONPs showed good compatibility, 86% (24 h) and67% (48 h) at 192 µM. [108]
Bare IONPs 10–13
Macrophages (mice) in RPMI
media
100 µg/mL 1 h MTT
No significant changes in viability after 1 h by all IONPs.
Bare IONPs produced highest ROS compared to PEG
and COOH-PEG-IONPs.
[109]PEG- IONPs 100
COOH-PEG-IONPs 100
PEG-550-IONPs
8–11
Bovine vascular smooth
muscle cells (VSMCs) in
DMEM media
100–1000 ppm 5–24 h
LIVE/DEAD
viability/Cytotoxicity
Kit
Dose dependent cytotoxic response was found.
PEG-2K showed higher cell viability compared to
PEG-10K at 100 ppm.
[110]
PEG-2K-IONPs
PEG-5K-IONPs
PEG-10K-IONPs
PEPABC: IONPs 36 ± 5 Mouse brain endothelial cellline (bEnd.3) in DMEM media 0–10 mg/mL 30 h Resazurin dye assay No cell death reported after 30 h exposure at 10 mg/mL. [110]
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Table 1. Cont.
Coating Agent Types of IONPs Diameter (nm) Type of Cells Dose IncubationTime Types of Assay Brief Results Ref.
Dextran
Dextran-IONPs 200–250
Head and neck squamous cell
carcinoma: tonsilla
(UT-SCC-60A) and the
metastasis (UT-SCC-60B) in
DMEM media
0.2–1.8 mM 0–120 h
MTT, Annexin-V
apoptosis detection
assay
MTT: Decreased cell toxicity of dextran-IONPs compared
to Resovist®
Annexin-V-apoptosis: no changes in cell viability when
cells were treated at the concentration of 1.8 mM.
[112]
Dextran-IONPs 100
Mouse melanoma cells (B16)
and Chinese hamster lung;
fibroblast cells (V79) in DMEM
media
0–400 µg/mL 24 h MTT Slight changes in the cell viability were noticed ascompared to control. [113]
Dextran-IONPs 9 9.12 ± 1.46 L L929 fibroblast cells 50–1000 µg/mL 24 h MTT Significant reduction in cell viability at 1 mg/mL. Cellswere 90% viable at 0.75 mg/mL. [114]
DEAE-dextran-IONPs 27–50
Murine mesenchymal
stem/stromal cell (MSC) in
DMEM media
50 µg/mL 3 h CCK-8 No significant changes I the cell viability were noticed. [115]
Bare Fe2O3 7
Human bone marrow
mesenchymal stromal
cells (hBMSCs)
hBMSCs-1: age 12 years;
hBMSCs-2: age 54 years in
α-modified eagle media
(αMEM)
15.4 g of iron/mL 72 h WST-1
The study compared physicochemical properties of bare
Fe2O3 and nanoparticles coated with different coating
agents.
hBMSCs-1: significant reduction in cell viability by
PLL-Fe2O3and mannose-Fe2O3 NPs;
hBMSCs-2: reduction in cell viability by all IONPs,
mostly by uncoated-Fe2O3 and PLL-Fe O NPs.
[116]
Endorem®(Fe3O4 coated
with dextran)
5.5
PLL PLL-Fe2O3 5.5
PLL-dextran PLL-Endorem 5.6
PDMAAm PDMAAm-Fe2O3 7.5
Mannose Mannose-Fe2O3 7
Mono-meric IONPs-R1 6.5–7.5 Murine primary brain cells
(primary microglia, primary
hippocampal neurons, and
neuron–glia co-cultures) in
DMEM media
0.5, 1.5 or 3.0 mM 6–24 h PI staining
Extended incubation and dose dependent cell death was
observed by all IONPs except Ferumoxytol. Ferumoxytol
surprisingly increased the number of viable cells.
IONPs-R1, R2 and Ferucarbotran were quickly ingested
by microglial cells compared to Ferumoxytol.
[117]
citrate layer IONPs-R2 7.5–8.7
Carboxy-dextran Ferucarbotran (Resovist®) 60
Carboxymeth-dextran Ferumoxytol (Feraheme®) 30
Chitosan
Bare IONPs 5 50-100 Human L-O2 hepatocytes in
RPMI media
1.25–20 µg/mL 24 h MTT
Bare IONPs showed more cytotoxicity compared to
FAPLCS-IONPs in L-O2 hepatocytes.
[118]
FAPLCS-IONPs 1 136.60 ± 3.90
Bare IONPs 1 18 Primary human osteoblast cells
(SV40) in DMEM media
20–300 µg/mL 48 h CCK-8
Decreased viability found when cells were treated with
bare IONPs at 100 and 300 µg/mL. [119]CS-IONPs 35
CS-IONPs 2–8 Cervical carcinoma cell lines(HeLa and SiHa) 0–1000 µg/mL 24 h XTT
Bare and CS-IONPs showed reduction in cell viability by
5% and 2% respectively.
SiHa cells showed 8% reduction in cell viability at
1000 µg/mL.
[120]
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Table 1. Cont.
Coating Agent Types of IONPs Diameter (nm) Type of Cells Dose IncubationTime Types of Assay Brief Results Ref.
Carbon Fe@C/C 5–140
Human (HTB140), murine
(B16-F10) melanoma cells and
human dermal fibroblasts
(HDF) in DMEM
0.0001–100 µg/mL 24 h MTT
Decreased cell viability in melanoma cells.
Murine melanoma cells were more sensitive to bare
IONPs than human cells. Fe@C-COOH and
Fe@C-CH2CH2-COOH showed weaker response to cells,
and 80–100% cells remained viable.
[121]
Abbreviations: TEOS: tetraethyl ortho silicate, APTMS: (3-aminopropyl) trimethoxysilane, PEG: polyethylene glycol, VTES: triethoxyvinylsilane, FITC: fluorescein isothiocyanate, PLL:
poly-L-lysine, DMSA: meso-2,3-dimeraptosuccinic acid, XTT: (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide), PEG-CS-PTH NPs: parathyroid hormone (PTH
1−34) loaded PEGylated chitosan nanoparticles, PEG-(550,2K,5K,10K)-IONPs: IONPs coated with PEGs of varying chain length, FAPLCS: folate-conjugated N-palmitoyl chitosan micelles,
DEAE-dextran-IONPs: diethylamino ethyl (DEAE)-Dextran coated IONPs, PEPABC: (poly(ethylene glycol)-poly(aspartate) block copolymers), CS-IONPs: chitosan coated IONPs, Fe@C/C:
bare carbon encapsulated IONPs, Fe@C-COOH, Fe@C-CH2CH2-COOH: carboxylic acid modified IONPs.
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3.2. Cell Viability
In an effort to determine cell viability, a number of assays correlated with either membrane
integrity, metabolic activity or functional capabilities have been developed. Exposure of cells to MNPs
can lead to plasmatic membrane disruption, allowing the release of cellular molecules, such as lactate
dehydrogenase (LDH), or the entry of molecules able to intercalate with nucleic acids(e.g., propidium
iodide, PI) [72]. Tetrazolium salts (e.g., MTT and XTT) are commonly used to determine cell viability, as
mitochondrial activity reduces these subtracts into formazan crystals [73–76]. The spectrophotometric
detection of these crystals between 450 and 570 nm might be hampered by the interference of the MNP
absorbance; thus, special care should be taken when selecting the assay conditions. Alternatively, cell
viability can be determined through fluorescence or luminescence using an adenosine triphosphate
(ATP)-based assay, that quantifies a product generated upon phosphorylation of glycerol; or a
live/dead assay, based on the simultaneous determination of live and dead cells (measures the
intracellular esterase activity and plasma membrane integrity). Th Resazurin cell viability assay is also
a reliable, sensitive and easy-to-use fluorescent assay that detects cellular metabolic activity as resazurin
(7-Hydroxy3H-phenoxazin-3-one 10-oxide), a non-fluorescent dye, is irreversibly reduced to the
highly red fluorescent resorufin by dehydrogenase enzymes in metabolically active cells. The Trypan
Blue dye exclusion test is commonly used to determine the number of viable cells present in a cell
suspension, as only live cells with intact membranes exclude the entry of the dye. Upon optical
microscope examination, a viable cell will have a clear cytoplasm, whereas a nonviable cell will have a
blue cytoplasm.
3.3. Cell Proliferation
Cell proliferation assays are mainly designed based on three concepts: analysis of metabolic
activity (previously described), measurement of the rate of DNA replication and, less commonly,
recognition of cell surface antigen [77]. The rate of DNA replication can be analyzed by using
radioactive (e.g., 3H-thymidine) or labelled nucleotide analogues (e.g., 5-bromo-2′-deoxyuridine,
BrdU). BrdU can be incorporated into DNA during proliferation and assessed by flow cytometry
or immunohistochemistry after addition of fluorescently-labelled antibodies specific for BrdU.
Alternatively, cells can be labelled with carboxyfluoresceinsuccinimidyl ester (CFSE), which is
incorporated into DNA during proliferation and is measured using a flow cytometer. The signal
is proportional to the quantity of CFSE incorporated into cells.
3.4. MNP Cellular Uptake Studies
Assessment of MNP-cell interactions should allow single cell analysis to discriminate surface
bound and internalized nanoparticles. Usually, cellular uptake studies involve imaging techniques and
flow cytometry methods [78]. Fluorescence microscopy-based techniques allow one to distinguish the
nanoparticle signal inside the cells from the different cellular constituents, as different labeling methods
can be applied. However, to reach a resolution in the nanometer range electron microscopy represents
a more suitable technique, allowing the localization of nanoparticles at the ultrastructural cell level.
Consequently, transmission electron and scanning electron microscopy techniques play an important
role in the evaluation of the cellular framework, including organelles and membrane structures [79].
It is important to note that electron microscopy only gives a static image of the sample, requiring an
immobilization step using a resin or cryogenic conditions. The flow cytometry-based approach
allows higher sample throughput and provides only qualitative information on cell-associated
nanoparticles. Analysis with flow cytometry usually requires fluorescent nanoparticles, but it is
also possible to analyze cellular association of non-fluorescent nanoparticles, taking advantage of
the side scatter function of flow cytometry [80] that identifies the cellular granularity. To distinguish
both surface-bound and internalized nanoparticles, the previously described imaging techniques
are recommended.
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3.5. Other Complementary Assays
The Caspase-3/7 green assay enables the flow cytometric detection of activated caspase-3 and
caspase-7 in apoptotic cells. Apoptosis can be evaluated by annexin V, an intracellular protein that
binds to phosphatidylserine in a calcium-dependent manner. Fluorochrome-labeled annexin V can
then be used to specifically target and identify apoptotic cells. To help distinguish between the
necrotic and apoptotic cells it is recommended to use PI or 7-amino-actinomycin D (7-AAD). Early
apoptotic cells will exclude PI or 7-AAD, while late-stage apoptotic cells will stain positively, due to the
passage of these dyes into the nucleus, where they bind to DNA. DNA fragmentation can be detected
via the TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) assay, as the DNA
strand breaks are detected by enzymatically labeling the free 3′-OH termini with modified nucleotides.
These new DNA ends are typically localized in morphologically identifiable nuclei and apoptotic
bodies. In contrast, normal or proliferative nuclei, which have relatively insignificant numbers of DNA
3′-OH ends, usually do not stain with the kit.
4. Sample Preparation for In Vivo Evaluation
With regard to MNP preparation, a pH solution range of 7.2± 0.6 should be considered mandatory.
Indeed, this neutral pH should avoid damaging the veins or inducing pain to the animals. To prevent
or reduce vascular complications, the osmolarity of the MNP solution also has to be considered [81].
A very small number of in vivo experiments have tested the direct cytotoxic effects on vascular
endothelial cells due to pH and/or osmolarity changes, after intravenous administration of drugs [81].
The viscosity and the rate of infusion are also very important to consider when administering MNPs
through vascular vessels [82].
MNPs should be tested alone in a magnetic field, and a frequency response profile should
be determined to optimize the MNP heating rates and establish the appropriate field/frequency
combination to set up the most favorable concentration for inducing HT in vitro and in vivo (dose
response vs. time). Then, a dose-response curve should be constructed, if possible (Figure 2). It is
possible that the MNPs themselves may be affected by the AMF and/or temperature changes [83].
Therefore, the properties of the MNPs [84] should be checked again after HT application (e.g., size
by DLS, shape by TEM). Indeed, the temperature at the surface of the MNPs could be different from
the surrounding environment due to heat transfer mechanisms in close proximity to the MNPs [85].
Yu and colleagues [86] have described a method based on the temperature-dependent thermodynamics
of the hybridization and denaturation of double-stranded DNA to evaluate the local temperature of
different MNPs during HT.
The delivery strategy has to be decided for the in vivo evaluation. Indeed, a systemic injection of
MNPs into the tumor does not face the same problems that a direct injection does. Recently, direct
injection of MNPs has been approved by the European Medicines Agency (EMA) for the treatment of
primary or recurrent glioblastoma multiforme, a lethal brain tumor with limited treatment options [53].
Systemic injection has the advantage that MNPs reach the tumor in a more uniform way (uniform
binding), which results in improved internalization [87]. However, in the blood stream, MNPs would
be subject to opsonization (i.e., the process by which an exogenous molecule is tagged for destruction
by phagocytosis) [45] and captured by the reticuloendothelial system (RES) [88]. To avoid these
problems, MNPs are coated with surfactants and polymers [45,88].
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A time interval of ~5 min was allowed before switching on the magnetic field, so that the system would
reach the thermal equilibrium state. The desirable magnetic field could be achieved by adjusting the
coil current via the EasyHeat system. A time step of 30 s was selected between consecutive temperature
recordings and the total heating process lasted 1500 s. Subsequently, the field was switched off,
but the data acquisition process was continued, in order to obtain the cooling phase of the fluid.
(Unpublished data).
In order to reach the targeted diseased area, MNPs have to be designed not only to avoid
uptakes but also to effectively penetrate into the tumor interstitium and to be taken up by cancer
cells. This introduces the concept of targeting strategies [89]. The two main strategies are passive
targeting and active targeting [45]. Passive targeting takes advantage of the abnormal vessels created
by cancer-induced angiogenesis, which have fissures through which MNPs may accumulate in the
tumor [45]. The success of passive targeting also depends on different physicochemical properties of
the MNPs such as particle size, surface charge and hydrophobicity [90]. Moreover, solid tumors show
the enhanced permeability and retention (EPR) effect for MNPs of appropriate size. The EPR effect
is due to defective vasculature [91] and deficient lymphatic drainage system in solid tumors, which
increase the pore size in the endothelial wall [90].
Active targeting relies on magnetic guidance of the MNPs using an external magnet, or through
interaction mediated by targeting ligands (i.e., antibodies, peptides) as presented with NPs [45,92].
An external magnetic field can attract and maintain MNPs into the area of interest. Pre-clinical and
clinical trials have produced very consistent results in cancer treatments [93–95]. Another way to
increase accumulation of MNPs in the tumor is to use biotargeting agents that specifically bind to
tumor cells. Yet another interesting approach to increase the concentration of MNPs in the tumor
tissue is to attach specific binding epitopes to the MNPs. For example, the RGD peptide (Arg-Gly-Asp)
is recognized by integrins expressed on the membrane of both colorectal carcinoma cells and the
endothelial cells of newly formed vessels in the tumor [96–98]. Thus, the identification of specific
integrins in the tumor models is the key to developing more selective MNPs [99].
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5. Magnetic Hyperthermia Combined with Radiation Therapy
Before beginning any pre-clinical experiments, one should have a clear understanding of the
physics, biology, radiobiology and physiology of the animal, the tumor, HT and RT. Several references
are provided in the Introduction. These can be used as a starting point for further research.
As with all experiments, a pre-clinical study should be carefully designed and all the relevant
factors that may affect the results should be considered. Below some of the more important ones
regarding MNP-mediated HT are discussed. We focus on HT because in contrast, RT technology,
equipment, algorithms, treatment planning and analysis software, quality assurance and procedures
are well-established and mature.
5.1. Animal Physiology
Understanding animal physiology is the key to a successful experiment. For example, one should
not forget that core body temperatures will fall significantly under anesthesia, so it is mandatory to
use a rectal probe to monitor this parameter and to artificially maintain the physiological temperature
of the animal during treatment [100–102] by placing, for example, the animal on a heated pad during
experimentation and postoperative period. Otherwise, the need of heating to achieve effective
hyperthermia would be unnecessarily increased. The administration of “foreign materials” (such
as MNPs), which will probably be affected by the immune system, also has to be taken under
consideration. Therefore, the use of immunocompromised animals may modify the outcomes of
these experiments.
5.2. Modelling and Simulations
Both MH and RT are physical processes with biological effects. As such, they naturally lead to
modelling and simulations. For example, physics modelling software can be used to estimate the
quantity and distribution of MNPs required to achieve the desired temperature in the tumor, under
different technical parameters, e.g., AMF frequency and strength, and physiological conditions, e.g.,
blood flow. In silico, biology software can be used to assess the effects of the two treatments [103].
5.3. Tumor Models
The tumor animal model should be considered before designing the HT treatments. Its characteristics
should mimic as closely as possible the vascularization pattern of the real human tumor.
Vascularization is very relevant because of its influence on the delivery of MNPs into the tumor
and dissipation of heat induced by MNPs. For example, in the Dunning model [104] of prostate cancer
(an established rat model developed to study prostate cancer progression), orthotopically-implanted
tumors display a more rapid growth and a higher resistance to HT than heterotopic tumors, an issue
which is possibly related to higher perfusion [105]. Direct implants of colorectal cancer cells in the rat
liver develop their vascularization from the arterial vessels and do not receive blood from the portal
vein [106]. However, tumors induced by subcutaneous tumor cell inoculation develop less stroma than
their correspondent orthotopic tumors [107]. The sites of tumor implantation are also important for
the experiments when direct administration of MNPs into the tumor tissue is chosen. Though imaging
techniques such as US and MRI can be used to track the needle inside the animals, there are fewer
complications when the tumors are easily accessible.
5.4. MNP Administration
Ideally MNPs should be administered by systemic injection [108] (e.g., intravenous or
intraperitoneal administrations), as this is a simple and safe procedure. However, at present,
this approach seems to have a low success rate in the accumulation of MNPs in the tumor [51].
In animal models, orientation has been attempted by systemically-administered MNPs using external
magnets [109] or biotargeting agents (see Section 4). Alternatively, MNP administration could be
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realized by direct injection into the tumor [53], intraarterially [110] or by MNP vehiculization near
the tumor using a catheter, which is a routine procedure in cancer therapy [111]. Several consecutive
injections can also be considered as a way to achieve a minimal concentration of MNPs in the tumor
tissue. In fact, this approach has been tried in some clinical settings. Direct injection is also preferred in
an attempt to avoid the accumulation of MNPs in the main organs of the reticuloendothelial system
(i.e., liver and spleen), which could lead to side effects with HT (see Section 5.6 Treatment).
5.5. Thermal Dosimetry
A critical issue in HT is how to measure the temperature distribution in the tumor and surrounding
tissue in real time. Temperature probes, such as optical fibers, are direct and accurate, but invasive.
Therefore, they run the risk of spreading the disease and, practically, only a limited number of them
can be used. Infrared imaging provides 2D measurements but is indirect since it measures the skin
rather than the tumor temperature. MRI can provide 3D temperature distributions, along with other
information that can be used to plan, improve and assess the heating process as well as the ability of the
tumor to be heated [48,112]. However, the presence of MNPs interferes with MRI thermometry [113].
Moreover, the availability of MRI units may be a problem, especially for pre-clinical experiments. MRI
units are generally found in hospitals, so using them for laboratory animals may run into legal or
regulatory issues, scheduling and disinfecting problems etc. Diffuse Optical Spectroscopic Imaging,
employing low power near-infrared light, has been used in clinical settings to assess deep tissue
temperature in breast cancer [114].
From the temperature map, various quantities that describe the heating achieved can be calculated.
An often-quoted one is CEM43T90, which is the cumulative equivalent minutes at 43 ◦C covering 90%
of the tumor. Although CEM43T90 is a single number for describing a spatially and temporally varying
temperature distribution [115,116], it has been shown to correlate well with clinical outcomes [117–120].
5.6. Treatment
The choice of treatment sequence should take into account the relevant radiobiological,
physiological and technical considerations, and may have a significant effect on the results.
The synergy between the two treatments appears to be maximal when they are administered
simultaneously [36,121,122]. However, the duration of the synergy and the optimal sequence
will probably depend on the cell type. For example, for Chinese hamster ovary cells (HA-1)
radiosensitization was much higher when heating preceded irradiation, but for mouse mammary
sarcoma cells (EMT-6) the opposite was true [123]. In HA-1 cells the synergistic effect lasted about
20 min [124], whereas in C3H mammary carcinoma and its surrounding skin, the effect lasted more
than one hour [18]. Interestingly, in the C3H mammary carcinoma study, radiosensitization was high
for both the tumor and normal skin when HT and RT were given simultaneously, but a differential
radiosensitization of tumor vs. normal skin was observed when there was an interval between the two
treatments, especially when HT was given 4–24 h after radiation.
In a typical HT session, the entire animal is placed inside the heating coil. Thus, all the MNPs
are excited, regardless of whether they are in the tumor or not. In contrast to HT, sophisticated
commercial and development small animal irradiation devices that can perform stereotactic irradiation,
image guidance, Monte Carlo dose calculation and proton irradiation are available [125–128]. These
specialized units can deliver highly conformal dose distributions, with sub-millimeter precision,
limiting the high-dose region to the tumor and sparing surrounding normal tissue. However, they
are not widely available. Yet, even in the case where irradiation is performed using fixed radioactive
sources, it is possible to reduce the exposed area by collimating the field.
5.7. Blood Flow
Heating causes the blood vessels to dilate, increases blood flow and enhances permeability
through the vessel walls. These, in turn, affect heat dissipation and tumor oxygenation and the
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microenvironment. The effect is non-uniform and depends on the temperature, heating pattern,
treatment sequencing as well as the tumor characteristics, such as its size [33,121,129–131]. In the case
of MNP-mediated HT, this may affect the MNP distribution and/or penetration in the tumor.
5.8. Thermotolerance
Heating represents a stress situation for cells and, at hyperthermic temperatures (max = 45 ◦C [132]),
they respond by expressing Heat Shock Proteins (HSP) that protect the cell from further damage [133–135].
This mechanism is not present at the very high temperatures reached in thermal ablation. HSPs function
as chaperones within the cell and protect cells from thermal damage by stabilizing unfolded proteins
to prevent aggregation. Although a lot remains to be elucidated regarding HSPs, such as their role in
cancer and the immune response [136–138], the practical result is that cells develop thermotolerance,
which may persist for 72 to 120 h [139]. Thus, HT is typically applied once or twice a week in the clinic,
whereas RT is applied daily.
5.9. Heating Profile
Radiosensitization depends on the heating rate and pattern, i.e., whether it is continuous at a
given temperature, interrupted or complex, consisting of successive heating at different temperatures.
For example, heating first at a lower temperature and then at a higher one (step-up heating) resulted
in radiosensitization that was marginally better than heating at a single temperature. The converse
pattern (step-down heating) was slightly better overall, with the added characteristic that the differential
sensitization between tumor and skin was increased [121,140–142].
5.10. Study Endpoints
The endpoints of the preclinical experiments should be carefully defined before the study begins,
as these may affect the design of the study. Complete Response (CR), which means that all detectable
tumor has disappeared, is often used in clinical studies [143–145]. Another important and practical
endpoint is cancer relapse. Therefore, one could plan the preclinical protocol to test the efficacy of HT
+ RT in the primary tumor and to investigate the absence or presence of relapse after treatment. It may
also be considered, in those models in which metastases develop from the primary induced tumor,
whether metastases are delayed or completely avoided by MNP treatment.
In addition, one should look at biochemical and/or histological markers to assess the effects
of HT. For example, tumor histological analysis could be done before and after treatment to assess
whether HT caused differentiation in the tumor profile. Or, since HSP90 [146] and the protein kinase
B/AKT (PKB/AKT) pathway are both inhibited after treatment with RT + HT, their expression levels
in tumor mass could be analyzed. Another interesting point is targeting cancer stem-like cells, which
are thought to be responsible for clinical relapses and are known to be extremely radioresistant. HT is
being studied as a means to induce radiosensitization of these cells [147].
5.11. Toxicity
Although the in vivo toxicity of the MNPs themselves must be determined and found acceptable
before the pre-clinical study, it is not clear that the same level of toxicity will hold when HT and RT
are applied. For example, in the presence of an alternating magnetic field, MNPs induce heat that
can be dissipated by the blood flow (heat transfer phenomenon), reducing the efficacy of HT [148].
To compensate this heat loss, the power of the alternating magnetic field and exposition time can be
increased to improve the efficacy of HT which can damage healthy cells. Therefore, in vivo toxicity
under application of HT and RT should also be investigated, e.g., by determination of biochemical
markers of liver function [e.g., gamma-glutamyl transferase (γ-GT), serum glutamic-oxaloacetic
transaminase (SGOT), alkaline phosphatase (ALP)], histological examination of different organs,
pharmacokinetic and biodistribution studies by liquid chromatography-tandem mass spectrometry
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(LCMS/MS), γ-imaging, MRI, CT, etc. In any case, iron oxide nanoparticles have been found to be
safe, as iron is biocompatible and degradable by human metabolism [149].
5.12. Treatment Evaluation
Long-term survival should be monitored for at least 60 days, since the growth rate of recurrent
tumors should not be different from that of the original tumor. In addition to determining whether
the treated tumors retained their tumorigenic properties after RT + HT treatment, tumors could be
digested 48 h after treatment and transplanted as single cells in limiting dilution into syngeneic
recipients [150,151]. Histological analysis of the newly formed tumor mass could then be performed.
The efficacy of RT + HT treatment could also be evaluated using the non-invasive MRI technique.
Indeed, based on their MRI contrast agent properties, MNPs could help to image tumors when they
are localized in the diseased site. MRI is, therefore, a perfect imaging technique to monitor changes of
the tumor volume following anticancer treatments. Together, these data should suggest that RT + HT
decreases the tumorigenicity of residual tumor cells and that the surviving cells form tumors that
have pathologic signs of histological differentiation with a less aggressive phenotype than either the
mock-treated tumors or the tumors treated with sub lethal doses of radiation.
Though limited success could be achieved in animal tumor models, any rate of success may be
clinically relevant as this procedure could be applied after major surgical removal of the tumor in order
to treat remnant tumor cells in the affected organ. Thus, it should be advised that when seeing some
degree of tumor reduction, new experiments with micrometastasis models would be of great interest.
At this stage, some histological samples from control animals (without HT and RT) could be used
to determine the internalization of MNPs into the cells. Whether the MNPs are inside or outside the
cells is very important and may differ from in vitro experiments. For example, PEG-functionalized
mesoporous silica-coated MNPs have a better heating performance when outside the cells [152].
TEM and Perl’s staining are the most suitable techniques for such investigations.
5.13. Analysis of Results
One should be careful when interpreting and analyzing the results from the combined treatment.
The interaction between radiation alone, without HT, and the animal or human is complex and
multifaceted. For example, radiation can simultaneously have an immunosuppressive as well as an
immunostimulant effect [153–156]. Which of the two dominates depends on many factors, including
dose, fractionation, and tumor type [157–160]. The addition of HT is an extra layer of complexity,
which makes it more difficult to fully understand the mechanisms that lead to cancer cell death.
6. Recommended Method for Pharmacokinetic and Biodistribution Studies of MNPs
6.1. Pharmacokinetics
Pharmacokinetics (PK) can help to make decisions about further preclinical investigations on
novel MNPs [161]. Since the chemical and physical properties of MNPs determine their in vivo
fate, it is desirable to measure PK profiles early in the development process so as to use that
information in MNP design and candidate prototype selection. Evaluation of absorption, distribution,
metabolism and excretion (ADME) of MNPs is essential. Four factors essentially determine PK of
MNPs: route of administration; particle size, shape and charge; nature of coating materials; and animal
species [162,163].
The radiotracer method is particularly suited for the study of pharmacokinetic parameters of
nanomaterials [164,165]. Measuring radiation from radioactive tracers attached to MNPs has been
shown to be a highly sensitive and specific method that allows for accurate quantification, without
limit to tissue penetration in any organ. The required radionuclide concentration is around 10−10 M at
the site of interest. Other methods are also available to evaluate biodistribution and PK parameters
of MNPs. From the innovative particle electron paramagnetic resonance (pEPR) method to the gold
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standard ICP-MS, various parameters, such as MNP concentration, can be evaluated in tissues and
organs [166]. In the present manuscript, we will focus on the radiotracer method.
6.2. Biodistribution Studies
Tissue/organ/tumor accumulation is expected to be dependent on the dose and time
post-injection, and hence time-course studies at different doses are important for full characterization.
Tissue accumulation should be determined for more than two time-points, in order to acquire as much
information on the PK of the injected MNPs as possible, which is crucial for developing design rules.
Important biodistribution information on the MNPs under evaluation can often be obtained
by radiotracer-based imaging (Figure 3) using either single-photon emission computed tomography
(SPECT) or PET, depending on the available radionuclides.Nanomaterials 2018, 8, x FOR PEER REVIEW  17 of 31 
 
Figure 3. Cumulative positron emission tomography (PET) / X-radiation (X-ray) images of a normal 
Swiss mouse injected with 68Ga-Fe3O4-2,3-dicarboxypropane-1,1-diphosphonic acid (DPD) MNPs at 
20, 30 and 60 min post-injection. The gradual alteration in color indicates a lower to higher number of 
recorded counts (Reproduced with permission from [167]). 
If PET or SPECT are not available, the information on in vivo biodistribution of the radiolabeled 
MNPs can be obtained by ex vivo biodistribution studies dissecting the animal, collecting blood, 
organs and tissues of interest and measuring the radioactivity arising from accumulated 
radiolabeled MNPs by gamma counter. The animals should be sacrificed via spinal cord dislocation 
at specific times after injection, depending on the physicochemical characteristics of the MNPs (size, 
surface charge etc.) and the half-life of the radionuclide used for radiolabeling. For nanometer-sized 
particles, recommended time-points for assessment are 30 min, 120 min, 24 h, 48 h, 72 h after i.v. 
administration, to monitor their retention and excretion pattern. The following organs should be 
removed, weighed and measured for radioactivity: heart, lungs, liver, kidneys, spleen, stomach 
(emptied), intestine (emptied), muscle (hind leg), the complete left femur, and a blood sample (0.5–1 
mL). All studies should be performed on at least three animals per time-point.  
If beta emitters are used, before measuring radioactivity the tissues should be homogenized 
and diluted with water to reach identical geometry and similar probe density for bremsstrahlung 
measurements. 
The uptake into the organs should be expressed as a percentage of the injected total 
radioactivity (% injected dose per organ) and per mL of blood, except for the radioactivity in the 
muscle, which should be estimated by assuming a muscle weight of 40% of the total body weight. 
Tissue uptake of the MNPs could be also expressed as % injected dose (ID) per gram (percentage of 
ID per gram tissue) at post-injection time. The data should be presented as mean values ± standard 
deviation for each group. Data should be decay-corrected for the nuclide used in each experiment. 
The precise injected activity is calculated by measuring the activity of the syringe, containing 
the radiolabeled MNPs, before and after injection, as a significant quantity of the labeled MNPs may 
be adsorbed onto the plastics of the syringe. 
6.3. Radiolabeling of MNPs, Selection of Radionuclides and Optimization of the Radiolabeling Procedure 
The selection criteria for radionuclides must be based on the physical data of the radionuclide 
and biological variables governing its use. The considerations for physical characteristics include the 
physical half-life, type of emissions, energy of the radiations, daughter products, method of 
production, and radionuclide purity. The biochemical aspects of the radiolabeled MNPs include 
tissue targeting, retention of radioactivity in the organ/tissue, in vivo stability, and toxicity. In 
contrast to MNP production, the radiolabeling process is time-limited and difficult because of the 
risk of contamination. The handling of radionuclides has to be carried out in specially designed 
radiochemical laboratories with controlled ventilation and air conditioning, shielded remote 
handling facilities, and special equipment for measuring the radioactivity of selected radionuclides. 
Particular attention must be paid to the potential impact of labeling on the properties of MNPs. An 
adapted labeling method will need to be used, to ensure that the labeling is not likely to modify the 
Figure 3. Cumulative positron emission tomography (PET) / X-radiation (X-ray) images of a normal
Swiss mouse injected with 68Ga-Fe3O4-2,3-dicarboxypropane-1,1-diphosphonic acid (DPD) MNPs at
20, 30 and 60 min post-injection. The gradual alteration in color indicates a lower to higher number of
recorded counts (Reproduced with permission from [167]).
If PET or SPECT are not available, the information on in vivo biodistribution of the radiolabeled
MNPs can be obtained by ex vivo biodistribution studies dissecting the animal, collecting blood, organs
and tissues of interest and measuring the radioactivity arising from accumulated radiolabeled MNPs
by gamma counter. The animals should be sacrificed via spinal cord dislocation at specific times after
injection, depending on the physicochemical characteristics of the MNPs (size, surface charge etc.) and
the half-life of the radionuclide used for radiolabeling. For nanometer-sized particles, recommended
time-points for assessment are 30 min, 120 min, 24 h, 48 h, 72 h after i.v. administration, to monitor their
retention and excretion pattern. The following organs should be removed, weighed and measured for
radioactivity: heart, lungs, liver, kidneys, spleen, stomach (emptied), intestine (emptied), muscle (hind
leg), the complete left femur, and a blood sample (0.5–1 mL). All studies should be performed on at
least three animals per time-point.
If beta emitters are used, before measuring radioactivity the tissues should be homogenized and
diluted with water to reach identical geometry and similar probe density for bremsstrahlung measurements.
The uptake into the organs should be expressed as a percentage of the injected total radioactivity
(% injected dose per organ) and per mL of blood, except for the radioactivity in the muscle, which
should be estimated by assuming a muscle weight of 40% of the total body weight. Tissue uptake of the
MNPs could be also expressed as % injected dose (ID) per gram (percentage of ID per gram tissue) at
post-injection time. The data should be presented as mean values ± standard deviation for each group.
Data should be decay-corrected for the nuclide used in each experiment.
The precise injected activity is calculated by measuring the activity of the syringe, containing the
radiolabeled MNPs, before and after injection, as a significant quantity of the labeled MNPs may be
adsorbed onto the plastics of the syringe.
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6.3. Radiolabeling of MNPs, Selection of Radionuclides and Optimization of the Radiolabeling Procedure
The selection criteria for radionuclides must be based on the physical data of the radionuclide
and biological variables governing its use. The considerations for physical characteristics include the
physical half-life, type of emissions, energy of the radiations, daughter products, method of production,
and radionuclide purity. The biochemical aspects of the radiolabeled MNPs include tissue targeting,
retention of radioactivity in the organ/tissue, in vivo stability, and toxicity. In contrast to MNP
production, the radiolabeling process is time-limited and difficult because of the risk of contamination.
The handling of radionuclides has to be carried out in specially designed radiochemical laboratories
with controlled ventilation and air conditioning, shielded remote handling facilities, and special
equipment for measuring the radioactivity of selected radionuclides. Particular attention must be paid
to the potential impact of labeling on the properties of MNPs. An adapted labeling method will need to
be used, to ensure that the labeling is not likely to modify the physicochemical properties of the MNPs
and hence their biodistribution. It will also be necessary to ensure that this marker is not “prematurely”
released from the MNPs, leading to potential confusion between monitoring of the released marker
and that remaining bound to the MNPs, as in this case the radionuclide distribution will not reflect
that of the MNPs. If the radiotracer method is used to follow the biodistribution (Figure 4), then the
minimum activity-dose necessary to measure radioactivity in a gamma counter should also be taken
into account for the radiolabeling.
As a matter of fact, Karageorgou et al. in a recent study [167] assessed the in vivo behavior of
68Ga-Fe3O4-DPD MNPs as potential PET/MRI imaging agents. They demonstrated that the ex vivo
biodistribution of the radionuclide mirrored the specific organ accumulation based on size and surface
charge of Fe3O4-DPD MNPs. 68Ga-Fe3O4-DPD MNPs were distributed throughout the organs, while in
the liver and spleen the uptake was the highest and the retention the longest at all time points examined,
due to the presence of Kupffer cells which are able to recognize and engulf 68Ga-Fe3O4-DPD MNPs
through phagocytosis. Moreover, the negative surface charge provided strong electrostatic repulsion
between MNPs, resulting in excellent solubility and stability in the bloodstream with satisfactory
blood retention at 30, 60, and 120 min post injection. The low lung uptake was attributed to possible
embolization caused by post-injection aggregation (Figure 4).
Nanomaterials 2018, 8, x FOR PEER REVIEW  18 of 31 
physicochemical properties f the MNPs and hence their biodistribution. It will also be necessary to 
ensure that this marker is not “prematur ly” released from the MNPs, leading to potenti l confusion 
between monitoring of the released marker and that remaining boun  to the MNPs, as in this case 
t e radionuclide distribution will not reflect that of the MNPs. If the radiotracer method is used to 
follow the biodistribution (Figure 4), then the minimum activity-d se necessary to measure 
radioactivity in a gamma counter should also be taken into account for the radiolabeling. 
s  tt r f f ct, r r  t l. in a rece t st y [167] ssessed t e i  i  i r f 
68Ga-Fe3O4-DPD MNPs as potential PET/MRI imaging agents. They demonstrated that the ex i  
i istri ti  of the radionuclide mirrored the specific organ accumulation based on size and 
surface charge of Fe3O4-D D MNPs. 68Ga-Fe3O4-DPD MNPs were distributed through ut the organs, 
while in the liver and s leen the uptake was the ighest and the retention the longest at all time 
points examined, due to the presence of Kupffer cells which are able to recognize and engulf 
68Ga-Fe3O4-DPD MNPs through phagocytosis. Moreover, the negative surface charge provided 
strong electrostatic repulsion between MNPs, resulting in excellent solubility and stability in the 
l stream with satisfactory blood retention at 30, 60, and 120 min post injection. The low lung 
uptake was attributed to possible embolization caused by post-injection aggregation (Figure 4). 
blo
od
he
art live
r
sp
lee
n
lun
g
kid
ne
y
sto
ma
ch
inte
stin
e
pa
ncr
ea
s
mu
scl
e
bo
ne
0
1
2
3
4
5
6
7
8
20
30
40
50
60
70
%
 IA
/g
 30 min
 60 min
 120 min
 
Figure 4. Ex vivo biodistribution study of 68Ga-Fe3O4-DPD MNPs in normal Swiss mice performed at 
30, 60, and 120 min post injection (Reproduced with permission from [167]). Due to the relatively 
short half-life of 68Ga (t1/2 = 68 min), the study was performed at the designated time-points, after i.v. 
injection of the radiolabeled MNPs (11.11 μg MNPs/100 μL per mouse). 
Technetium-99m (99mTc), indium-111 (111In), gallium-67 (67Ga), and iodine-125 (125I) are the most 
frequently used γ-emitting radionuclides for MNP radiolabeling. Of these, 99mTc is the most common 
due to its favorable physical properties, such as its half-life, that allow for prolonged in vivo imaging 
and γ-photon single energy emission at 140 keV, which is beneficial for effective imaging. 
Radiometals, both diagnostic (64Cu, 68Ga, and 89Zr) and therapeutic (90Y and 177Lu), are best 
attached to MNPs via chelation.90Y is a high energy β-emitter with optimal nuclear-physical 
characteristics (decay half-life 64.1h, Emaxβ of 2.27 MeV) for radionuclide tumor therapy. Since 
labeling with different radionuclides most often requires new optimization of the procedure, 90Y is 
the radionuclide of choice for MNP-radiolabeling since it can be used for varied desirable purposes, 
from MNP tracking to the possible application in radionuclide therapy. 
In recent years, the use of PET isotopes with a relatively long half-life, such as 64Cu (half-life 
12.7h), and 89Zr (half-life 78.4 h), as well as the short-lived 68Ga (half-life 68 min), has increased. 
Especially the use of 68Ga (positron emission intensity 87%) is on the rise due to several identifiable 
properties of this radionuclide [168]. These include a superior image quality to that provided by 
i re 4. x vivo biodistribution study of 68Ga-Fe3O4-DPD MNPs i normal Swiss mice performed
at 30, 60, and 120 min post injection (Reproduced with permission from [167]). Due to the r l ti l
s rt lf-lif f Ga (t1/2 = 68 min), the study was performed at the designated time-points, after i.v.
i j ti f t i l l ( . µ 100 µL per ouse).
Nanomaterials 2018, 8, 306 19 of 31
Technetium-99m (99mTc), indium-111 (111In), gallium-67 (67Ga), and iodine-125 (125I) are the most
frequently used γ-emitting radionuclides for MNP radiolabeling. Of these, 99mTc is the most common
due to its favorable physical properties, such as its half-life, that allow for prolonged in vivo imaging
and γ-photon single energy emission at 140 keV, which is beneficial for effective imaging.
Radiometals, both diagnostic (64Cu, 68Ga, and 89Zr) and therapeutic (90Y and 177Lu), are
best attached to MNPs via chelation.90Y is a high energy β-emitter with optimal nuclear-physical
characteristics (decay half-life 64.1h, Emaxβ of 2.27 MeV) for radionuclide tumor therapy. Since labeling
with different radionuclides most often requires new optimization of the procedure, 90Y is the
radionuclide of choice for MNP-radiolabeling since it can be used for varied desirable purposes,
from MNP tracking to the possible application in radionuclide therapy.
In recent years, the use of PET isotopes with a relatively long half-life, such as 64Cu (half-life 12.7h),
and 89Zr (half-life 78.4 h), as well as the short-lived 68Ga (half-life 68 min), has increased. Especially the
use of 68Ga (positron emission intensity 87%) is on the rise due to several identifiable properties of this
radionuclide [168]. These include a superior image quality to that provided by SPECT radionuclides
and the potential for on-demand production via a generator (68Ge/68Ga-generator).
6.4. Prediction of the Biodistribution Based on the Physicochemical Characteristics of MNPs
Systemically injected MNPs are rapidly cleared from the blood stream by the reticuloendothelial
system mainly through the liver, spleen, and bone marrow, resulting in a low therapeutic index.
Opsonization is the major factor that induces mononuclear phagocytic system (MPS) uptake of MNPs.
Development of MNPs that avoid rapid clearance is a necessary requirement for sufficient delivery to
the desired target. MNPs with an extremely high circulation half-life should also be avoided as this may
contribute to off-target tissue toxicity and reduced signal-to-noise ratio due to non-specific binding.
6.5. Particle Size and Charge Influence Biodistribution
The hydrodynamic size of MNPs is one of the most important factors that determine their
biodistribution kinetics. Particle size plays a key role in clearance of these materials from the body,
with small particles (<10 nm) being cleared via the kidneys, and larger particles (>10 nm) being cleared
through the liver and the MPS. MNPs that have a mean diameter of approximately 100 nm show
prolonged blood circulation and a relatively low rate of MPS uptake. In the in vivo biodistribution
study, the high tumor uptake exhibited by slightly negatively charged MNPs might be due to their
prolonged blood circulation time. On the contrary, rapid clearance of highly charged MNPs by the RES
resulted in relatively short half-life and low tumor uptake [169]. As MNPs are mainly eliminated by
the phagocytic uptake in the RES and the liver is the main organ in the RES, the extent of sequestration
of MNPs by the liver has been reported to correlate with the level of blood retention. The average
particle size and polydispersity index of surface-modified MNPs can be determined by DLS.
6.6. The Nature of Coating Polymer Influences MNPs Pharmacokinetics
The surface characteristics of MNPs greatly influence their PK. Coating materials such as chitosan
can sterically stabilize the corona and prevent aggregation of MNPs. Surface modification of MNPs
with synthetic polymers like polyethylene glycol (PEG), polyvinyl alcohol (PVA), or polysaccharide can
enhance solubility of hydrophobic materials, minimize non-specific binding, prolong circulation time,
and enhance tumor-specific targeting. Generally, MNPs that have a mean diameter of approximately
100 nm with a neutral and hydrophilic polymer-extended surface exhibit prolonged blood circulation
and an increased level of tumor delivery.
6.7. The Surface Charge of MNPs Modifies Their Biodistribution
The surface charge of MNPs depends directly on the molecular structure of the coating materials.
The charge affects the degree of protein adsorption onto the MNPs surface. Due to charge-related
adsorption by serum proteins, purely anionic or cationic charge increases the hydrodynamic diameter
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to >15 nm. According to literature data, liver uptake of charged particles is greater than that of neutral
particles. Neutral MNPs exhibit a decreased rate of MPS uptake and prolonged blood circulation
compared to charged ones. The zeta potential has been routinely used as a parameter for estimating
the surface charge of MNPs.
6.8. Injected Quantity (Dose) of MNPs for Pharmacokinetic and Biodistribution Studies
The dose of MNPs is an important factor that can affect their PK and biological behavior. Therefore,
the optimum doses of MNPs should be determined. Dose is expressed as weight of MNPs per unit
weight of test animal (e.g., mg/Kg). Note, however, that in the case of radiolabeled MNPs the term
“dose” may refer to the activity per unit weight (e.g., Bq/kg or Ci/kg), rather than their quantity.
Determination of the administered dose is necessary since the fate of certain MNPs in the body
may differ according to the dose: urinary elimination is characteristic for low MNP concentration;
transfer to the liver, biliary excretion and elimination in stools for moderate MNP concentration and
finally liver storage in Kupffer cells (agglomerate and aggregate formation) is characteristic for high
MNP concentration.
For i.v. administration, the maximum volume of liquid that can be administered as a single
injection depends on the size of the animal used and route of administration. For mice and rats,
a possible maximal i.v. administration volume that is considered good practice is 5 mL/Kg [170].
The essential requirement is to ensure that the volume given causes minimum discomfort and does
not result in physiological or pathological changes that would compromise the experiment. Variability
in test volumes should be minimized by adjusting the concentration to ensure a constant volume at all
dose levels.
For intratumoral injection, up to 20% volume may be administered with limited leakage to the
body, depending on tumor composition, density, vasculature and interstitial pressure. Immediately
after injection, the application site should be covered and wiped twice with absorbing paper to retrieve
any MNPs leaking out of the tumor.
6.9. Requirements for Animal Experimentation
Variation in animal models (e.g., mouse, rat, pig) and differences in MNP concentration compared
to humans should be carried out. All experiments must be approved by the Institutional Animal
Ethical Committee and performed in accordance to the guidelines of the local ethical committee.
The request to the ethical committee should be sent as soon as possible since acquiring approval
takes time, depending on the country, from one to several months. Animals should be maintained on
standard pellet diet with free access to water in a 12-h light and dark cycle.
At least 3 animals should be used at each dose level and time point. However, power analysis
should be carried out to statistically determine the optimum number of animals per group. Indeed,
too small a sample size can miss the real effect in an experiment, whereas too large a sample size may
lead to unnecessary wasting of resources and animals [171], and is not in accordance with the “3Rs”
principle (Replacement/Reduction/Refinement) of animal experimentation. The animals should be of
the same sex. If females are used, they should be non-pregnant. The weight variation in animals used in
a test should not exceed ±20% of the mean weight, since this also affects biodistribution. Measurement
of most biochemical parameters is traditionally performed under standardized conditions, which
include overnight fasting, in order to achieve a more controllable metabolic environment and eliminate
variations, thus achieving uniformity in the environment.
6.10. Route of Administration
Basic PK studies should be performed by i.v. administration of MNPs through the tail vein. It is
important to know the plasma half-life of the injected MNPs (i.e., the time between injection and
elimination from the blood) and utilize this data to tune the characteristics of the MNPs, based on the
desired circulation time for each specific application.
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Biodistribution of MNPs in the animals after intra-peritoneal route should be similar to that of i.v.
administration; the highest concentrations of MNPs should be observed in the liver and the spleen.
However, the blood flow also takes them to other organs, e.g., the lungs.
Intratumoral administration of MNPs is used to concentrate them in the tumor. However, a small
quantity can also be found in other organs throughout the body, e.g., liver, lungs, lymph nodes, brain,
spleen, which depends on leakage of the tumor vasculature.
6.11. Metabolism and Excretion
It is important to determine the nature of the degradation products of MNPs, along with their
elimination mechanism and kinetics, especially as these metabolites may possess certain toxic effects.
The desired clearance mechanism can be a factor in the design of MNPs. Radiotracer methods can be
applied to follow excretion of MNPs measuring the radioactivity in the kidneys, bladder for hydrophilic
based coated MNPs and in liver and intestines for hydrophobic MNPs.
Metabolite assessment in urine, blood and other organs can be performed at various time points
after MNP administration, to determine whether the MNPs are metabolized after their administration
to the animal [172].
• In urine: Urine is collected at the time of sacrifice and is centrifuged before High-performance
liquid chromatography (HPLC) analysis;
• In serum: Blood is collected at the time of sacrifice and allowed to clot. After sample centrifugation
(10 min, 2000× g), the supernatant is carefully removed, treated with twice the volume of cold
ethanol and centrifuged once again. The supernatant is subjected to HPLC analysis;
• In other organs (and tumor, if relevant): The organ sample is cut into small pieces and
homogenized, after addition of ice-cold Phosphate-buffered saline (PBS) solution. The resulting
homogenate is centrifuged (15 min, 2000× g), filtered through a 0.2 µm filter and analyzed
by HPLC.
6.12. Elemental Analysis by Inductively Coupled Plasma Mass Spectroscopy
An alternative to using the radiotracer method to measure tissue accumulation of MNPs is to use
inductively coupled plasma mass spectroscopy (ICP-MS) to determine the amount of one or more
elemental components in the delivery system, for comparison to the initial components present [173].
Digestion of the samples for ICP measurements should be performed in an Advanced Microwave
Digestion System as follows: whole organs for biodistribution studies should be precisely weighed
and mixed in quartz inserts with 5 mL nitric acid (HNO3) and then heated in a microwave. Digestion
should be conducted for 20 min at a constant temperature of 200 ◦C, with a prior warm-up linearly over
10 min to 200 ◦C. After total mineralization and cooling to room temperature, and without filtration,
the solutions should be diluted to a fixed volume in 10 mL volumetric flasks with ultra-pure water
with a conductivity of 0.055 µS/cm. The content of Fe in the digested sample solutions can then be
determined by ICP-MS.
7. Conclusions
Hyperthermia in combination with Radiation Therapy is already used in a limited number of
hospitals and will probably play an important role in future cancer therapies. Unlike Radiation
Therapy, however, which is a well-established treatment in cancer management, Hyperthermia
needs to overcome several practical difficulties that have, so far, prevented it from realizing its
full potential. Magnetic Hyperthermia, mediated by MNPs, is a novel approach that may be the
answer to those problems. In this work, we have outlined the tests and considerations, after synthesis
and characterization of the MNPs, that a researcher must address in order to perform pre-clinical
testing. We have discussed in vitro evaluation of MNPs, in vitro evaluation of MNP-cell interactions,
in vivo evaluation of the MNPs, Magnetic Hyperthermia combined with Radiation Therapy, and PK
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and biodistribution studies of MNPs. As MNP-mediated Hyperthermia is a new field that has not
matured yet, we hope that this review will help establish guidelines and protocols that will lead to
clinical application.
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BrdU 5-bromo-2′-deoxyuridine
CFSE CarboxyFluoresceinSuccinimidyl Ester
CT Computed Tomography
DLS Dynamic Light Scattering
γ-GT Gamma-glutamyl transferase
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PET Positron Emission Tomography
PK Pharmacokinetic
PI Propidium Iodide
RES Reticuloendothelial System
RT Radiation Therapy
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